[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-440676-105":59,"doc-detail-440676-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","nanling-roxadustat-effectivenesssafety-in-chronic-kidney-disease-associated-anemia-with-peritoneal-dialysis","NANLING - Roxadustat Effectiveness/Safety in Chronic Kidney Disease-Associated Anemia with Peritoneal Dialysis","","Oral anemia therapies are preferred by patients receiving home-based peritoneal dialysis (PD). This phase 4 study assessed the effectiveness and safety of oral roxadustat in Chinese patients with chronic kidney disease (CKD)-associated anemia on PD. Patients received roxadustat thrice weekly for 24 weeks, evaluating hemoglobin response (including stratification by type 2 diabetes mellitus), quality-of-life changes via FACT-An and SF-36, and treatment-emergent adverse events. Roxadustat corrected anemia regardless of baseline T2DM, with adverse events consistent with the known safety profile.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanling-roxadustat-effectivenesssafety-in-chronic-kidney-disease-associated-anemia-with-peritoneal-dialysis/440676/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanling-roxadustat-effectivenesssafety-in-chronic-kidney-disease-associated-anemia-with-peritoneal-dialysis/440676.png","ImageObject",300,407,{"name":92,"@type":93},"dabgoudw","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this study?","Question",{"text":112,"@type":113},"To evaluate the effectiveness and safety of oral roxadustat for CKD-associated anemia in Chinese patients receiving peritoneal dialysis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was roxadustat administered and for how long?",{"text":117,"@type":113},"Patients received roxadustat three times weekly for 24 weeks in this phase 4 study.",{"name":119,"@type":110,"acceptedAnswer":120},"What hemoglobin endpoint was used to measure effectiveness?",{"text":121,"@type":113},"The primary effectiveness measure reported was the proportion achieving hemoglobin concentration ≥100 g/L at Weeks 20 and 24, overall and by T2DM status.",{"name":123,"@type":110,"acceptedAnswer":124},"Did roxadustat safety results align with expectations?",{"text":125,"@type":113},"Treatment-emergent adverse events occurred in 81.0% of patients, and roxadustat-related events occurred in 10.3%, consistent with roxadustat’s known safety profile and PD patient characteristics.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},440676,1790717083,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},3985747860484,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Kidney Diseases  \nResearch Article  \nKidney Dis 2026;12:1–17 DOI: 10. 1159/000549723  \nReceived: June 30, 2025  \nAccepted: October 29, 2025  \nPublished online: November 24, 2025  \nNANLING: Roxadustat Effectiveness/Safety in Chronic Kidney Disease-Associated Anemia with Peritoneal Dialysis  \nZhiming Yea Gang Xu b Hao Zhang c Liang Wangd Aiping Yine Hong Liu f Xiao Yangg Hui Zhongh Fei Xiongi Zhenhua Yangj Jie Dongk Hongtao Yangl Yiqing Wu m Cuihua Huang m Shuting Pan n Xueqing Yu a on behalf ofthe NANLING Working Group  \naDepartment of Nephrology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, PR China; bDepartment of Nephrology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, PR China; cDepartment of Nephrology, The Third Xiangya Hospital of Central South University, Changsha, PR China; dDepartment of Nephrology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, PR China; eDepartment of Nephrology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, PR China; fDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, PR China; gDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China; hDepartment of Nephrology, West China Hospital of Sichuan University, Chengdu, PR China; iDepartment of Nephrology, Wuhan No. 1 Hospital, Wuhan, PR China; jDepartment of Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China; kDepartment of Nephrology, Peking University First Hospital, Beijing, PR China; lDepartment of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, PR China; mMedical Affairs Department, FibroGen (China), Medical Technology Development Co. Ltd., Beijing, PR China; nClinical Biometrics Department, FibroGen (China), Medical Technology Development Co. Ltd., Beijing, PR China  \nKeywords  \nAnemia · Chronic kidney disease · Peritoneal dialysis · Roxadustat · Type 2 diabetes  \nAbstract  \nIntroduction: Oral anemia treatments are preferred by patients on home-based peritoneal dialysis (PD). We evaluated the effectiveness and safety of oral roxadustat in Chinese patients with chronic kidney disease (CKD)-associated anemia on PD. Methods: In this phase 4 study, patients with CKD-anemia on PD received roxadustat thrice weekly for 24 weeks. We assessed the  \nproportion with hemoglobin ≥100 g/L at Weeks 20 and 24 (overall and stratified by type 2 diabetes mellitus [T2DM] vs. nondiabetes mellitus [DM]), quality of life changes according to the Functional Assessment of Cancer Therapy-Anemia (FACT-An), and 36-Item Short Form Health Survey (SF-36), and safety. Results: Overall, 195 patients (116 male [59.5%]; mean ± standard deviation age, 46.3 ± 12.3 years) were enrolled; 189  \nTrial registration: China Clinical Trial Registry (ChiCTR2100044799, [https://www.chictr.org.cn/](https://www.chictr.org.cn/)).  \nThe individual names of the NANLING Working Group members are provided in the online supplementary material.  \n[karger@karger.com](karger@karger.com)[ ](karger@karger.com)[www.karger.com/kdd](www.karger.com/kdd)  \n© 2025 The Author(s) .  \nPublished by S. Karger AG, Basel  \nCorrespondence to:  \nXueqing Yu, yuxueqing [gdph.org.cn](gdph.org.cn)  \nThis article is licensed under the Creative Commons AttributionNonCommercial 4.0 International License (CC BY-NC) ([https://www](https://www). [karger.com/Services/OpenAccessLicense](karger.com/Services/OpenAccessLicense)). Usage and distribution for commercial purposes requires written permission.  \n(96.9%) were erythropoiesis-stimulating agent-treated and 43 (22.1%) had T2DM. Baseline hemoglobin was 98.1 ± 10.7 g/Land was \u003C80 g/L in 10 (5.1%). The mean (95% confidence interval) proportion who achieved a hemogl","cbCainjDJJPu0MZ9","https://ap.wps.com/l/cbCainjDJJPu0MZ9","pdf",3030910,17,"English","# Introduction\n## Study methods and outcomes\n## Results\n## Conclusion","[{\"question\":\"What is the purpose of this study?\",\"answer\":\"To evaluate the effectiveness and safety of oral roxadustat for CKD-associated anemia in Chinese patients receiving peritoneal dialysis.\"},{\"question\":\"How was roxadustat administered and for how long?\",\"answer\":\"Patients received roxadustat three times weekly for 24 weeks in this phase 4 study.\"},{\"question\":\"What hemoglobin endpoint was used to measure effectiveness?\",\"answer\":\"The primary effectiveness measure reported was the proportion achieving hemoglobin concentration ≥100 g/L at Weeks 20 and 24, overall and by T2DM status.\"},{\"question\":\"Did roxadustat safety results align with expectations?\",\"answer\":\"Treatment-emergent adverse events occurred in 81.0% of patients, and roxadustat-related events occurred in 10.3%, consistent with roxadustat’s known safety profile and PD patient characteristics.\"}]","NANLING - Roxadustat Effectiveness/Safety in Chronic Kidney Disease-Associated Anemia with Peritoneal Dialysis | PDF",1790692930,43]